We have to cover medical nutrition therapy for those who need it most, including Medicare beneficiaries. Almost all commercial payers are already doing this - the government needs to catch up.
The weight loss market is at yet another inflection point. The euphoria of the past three years is now confronting the realities of how obesity medications will scale to address an epidemic that impacts over 1 billion people globally.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Microdosing won’t be the right choice for everyone. But for many patients, it’s already proving to be the difference between quitting obesity treatment early and making lasting progress.
Instead of viewing obesity as one uniform condition, experts now recognize that it can arise from multiple biological patterns. Understanding that difference could finally change how we approach treatment altogether.
Withings Health Solutions added Ilant Health to its Obesity Care Network and shared best practices to improve patient monitoring, engagement and outcomes.
As scientists and researchers figure out the right balance of GLP-1 to glucagon ratio and a better drug delivery method, we are beginning to turn the page for the many individuals suffering from obesity.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
The Alliance for Women’s Health and Prevention and several other organizations are urging employers to cover the "full range of evidence-based obesity care options," including medical nutrition therapy, intensive behavioral therapy, surgery and medications.
Obesity care company knownwell expanded into six new clinic locations across greater Chicago. The company now operates eight clinics, as it has existing locations in Boston and Dallas. Knownwell also provides virtual care services to patients across New England, Texas and Illinois.
Combining AI-driven insights with tailored care pathways, patients gain access to health coaches, psychologists, and treatment plans, while providers benefit from workflow optimization.
Pricy GLP-1 medications are here to stay — let's focus on turning their potential into lasting, meaningful impact.
Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
Nutrition isn’t a supplement — it’s foundational to metabolic health. It’s time we integrate more ‘Food as Medicine’ initiatives alongside the GLP-1 therapies that are gaining traction.
As multi-billion investment continues to pour into the R&D of future obesity medications, the need for evidence generation of health benefits beyond short-term weight loss will be critical to the decision-making of healthcare providers and payers.
With so many now seeking GLP-1 treatment, we must find ways to help providers care for more patients. Technology is the key to unlocking this capacity.
Employers are in a unique position to drive change in obesity care, but face several challenges. Experts shared numerous strategies employers can implement.
Ilant Health extended its seed round from $3 million to $5.5 million. The company garnered interest from LifeX Ventures, Celtic House Asia Partners and Cornucopian Capital.